Literature DB >> 17706162

Chronic lymphocytic leukemia: biology and current treatment.

Clive S Zent1, Neil E Kay.   

Abstract

There has been considerable recent progress in understanding of the biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). These accomplishments have been accompanied by progressive improvement in the management of CLL and its complications. This review summarizes these changes and provides guidelines for a comprehensive approach to patient care.

Entities:  

Mesh：

Year:  2007        PMID： 17706162     DOI： 10.1007/s11912-007-0046-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  65 in total

1.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

Authors:  Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.

Authors:  D F Jelinek; R C Tschumper; S M Geyer; N D Bone; G W Dewald; C A Hanson; M J Stenson; T E Witzig; A Tefferi; N E Kay
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

Review 3.  Stem cell transplantation for chronic lymphocytic leukaemia.

Authors:  S Paneesha; D W Milligan
Journal:  Br J Haematol       Date:  2005-01       Impact factor: 6.998

Review 4.  How I treat refractory CLL.

Authors:  Emili Montserrat; Carol Moreno; Jordi Esteve; Alvaro Urbano-Ispizua; Eva Giné; Francesc Bosch
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

5.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.

Authors:  S Ibrahim; M Keating; K A Do; S O'Brien; Y O Huh; I Jilani; S Lerner; H M Kantarjian; M Albitar
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

6.  Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).

Authors:  Dolores Caballero; Jose A García-Marco; Rodrigo Martino; Victoria Mateos; José M Ribera; José Sarrá; Angel León; Guillermo Sanz; Javier de la Serna; Rafael Cabrera; Marcos González; Jorge Sierra; Jesús San Miguel
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

7.  Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.

Authors:  Maria Ilaria Del Principe; Giovanni Del Poeta; Francesco Buccisano; Luca Maurillo; Adriano Venditti; Antonella Zucchetto; Rita Marini; Pasquale Niscola; Maria Antonietta Irno Consalvo; Carla Mazzone; Licia Ottaviani; Paola Panetta; Antonio Bruno; Riccardo Bomben; Giovanna Suppo; Massimo Degan; Valter Gattei; Paolo de Fabritiis; Maria Cantonetti; Francesco Lo Coco; Domenico Del Principe; Sergio Amadori
Journal:  Blood       Date:  2006-04-06       Impact factor: 22.113

8.  Solid tumors after chronic lymphocytic leukemia.

Authors:  M Hisada; R J Biggar; M H Greene; J F Fraumeni; L B Travis
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

9.  Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study.

Authors:  Per Ljungman; Hareth Nahi; Annika Linde
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

10.  VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.

Authors:  Yean K Lee; Nancy D Bone; Ann K Strege; Tait D Shanafelt; Diane F Jelinek; Neil E Kay
Journal:  Blood       Date:  2004-03-02       Impact factor: 22.113
View more
  3 in total

1.  Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia.

Authors:  Lynda B Bennett; Kristen H Taylor; Gerald L Arthur; Farahnaz B Rahmatpanah; Sam I Hooshmand; Charles W Caldwell
Journal:  Epigenomics       Date:  2010-02-01       Impact factor: 4.778

2.  Large-scale analysis of DNA methylation in chronic lymphocytic leukemia.

Authors:  Farahnaz B Rahmatpanah; Stephanie Carstens; Sam I Hooshmand; Elise C Welsh; Ozy Sjahputera; Kristen H Taylor; Lynda B Bennett; Huidong Shi; J Wade Davis; Gerald L Arthur; Tait D Shanafelt; Neil E Kay; James E Wooldridge; Charles W Caldwell
Journal:  Epigenomics       Date:  2009-10       Impact factor: 4.778

3.  Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy.

Authors:  Ali Sakhdari; Guilin Tang; Lawrence E Ginsberg; Cheryl F Hirsch-Ginsberg; Carlos E Bueso-Ramos; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Case Rep Pathol       Date:  2019-03-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.